Back to Search
Start Over
Cancer-associated fibroblasts in neoadjuvant setting for solid cancers.
- Source :
-
Critical Reviews in Oncology/Hematology . Jan2024, Vol. 193, pN.PAG-N.PAG. 1p. - Publication Year :
- 2024
-
Abstract
- Therapeutic approaches for cancer have become increasingly diverse in recent times. A comprehensive understanding of the tumor microenvironment (TME) holds great potential for enhancing the precision of tumor therapies. Neoadjuvant therapy offers the possibility of alleviating patient symptoms and improving overall quality of life. Additionally, it may facilitate the reduction of inoperable tumors and prevent potential preoperative micrometastases. Within the TME, cancer-associated fibroblasts (CAFs) play a prominent role as they generate various elements that contribute to tumor progression. Particularly, extracellular matrix (ECM) produced by CAFs prevents immune cell infiltration into the TME, hampers drug penetration, and diminishes therapeutic efficacy. Therefore, this review provides a summary of the heterogeneity and interactions of CAFs within the TME, with a specific focus on the influence of neoadjuvant therapy on the microenvironment, particularly CAFs. Finally, we propose several potential and promising therapeutic strategies targeting CAFs, which may efficiently eliminate CAFs to decrease stroma density and impair their functions. [Display omitted] • This paper summarizes the results of the latest research advances related to CAFs. • A summary of the changes in CAFs after different types of neoadjuvant therapy has been made. • A detailed accountof the impact altered CAFs after neoadjuvant therapy may have on clinical therapeutic interventions. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10408428
- Volume :
- 193
- Database :
- Academic Search Index
- Journal :
- Critical Reviews in Oncology/Hematology
- Publication Type :
- Academic Journal
- Accession number :
- 174579067
- Full Text :
- https://doi.org/10.1016/j.critrevonc.2023.104226